Good Clinical Practice (GCP)
Full course · Clinical Research Foundations
Free Lesson Preview
This lesson is part of a complete GCP track — 2 courses, quizzes, a final exam, and a free verifiable credential. The optional $29 PDF certificate is recognized by 18+ trial sponsors.
Start learning for freeAlready enrolled? Sign in
Explore how Phase II trials establish whether an investigational drug works in patients with the target condition, determine optimal dosing, and inform critical go/no-go decisions.
What you will learn6 objectives
By the end of this lesson, you will be able to:
Phase II clinical trials represent a fundamental transition in drug development. Where Phase I focused primarily on safety in healthy volunteers, Phase II focuses on effectiveness in patients who actually have the condition the drug is intended to treat. This shift changes everything about how trials are designed and conducted.
The primary goals of Phase II are threefold. First, researchers seek preliminary evidence of efficacy: Does this drug produce measurable biological or clinical effects in the target patient population? Second, they work to identify optimal dosing: What dose or range of doses produces the best balance of efficacy and safety? Third, they continue to assess safety, but now in patients whose underlying disease and concurrent medications may affect how they respond to the investigational drug.
Phase II is often called "proof of concept" because it answers a conceptual question that preclinical research could only hypothesize about: Will the mechanism of action that worked in laboratory models translate into therapeutic benefit in humans? A drug might block a receptor perfectly, might achieve the expected blood levels, might even produce the anticipated biochemical changes, and still fail to help patients. Phase II is where that translation is tested.
Progress saves itself — finish reading and this lesson completes
